{"nctId":"NCT01388361","briefTitle":"Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin","startDateStruct":{"date":"2011-09"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":413,"armGroups":[{"label":"IDeg (non-randomised)","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]},{"label":"IDeg + IAsp","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec","Drug: insulin aspart"]},{"label":"IDeg + liraglutide","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec","Drug: liraglutide"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin aspart","otherNames":[]},{"name":"liraglutide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).\n* The subject must have completed the end of treatment visit of NN1250-3643 with Insulin degludec once daily + metformin.\n* Ability and willingness to adhere to the protocol including self measurement of plasma glucose according to the protocol\n\nExclusion Criteria:\n\n* Participated in NN1250-3643 and treated with insulin glargine\n* Previous treatment with glucacon like peptide (GLP-1) receptor agonists (e.g. exenatide, liraglutide)\n* Impaired liver function, defined as alanine aminotransferase (ALAT) 2.5 times the upper limit of normal at end of treatment in NN1250-3643\n* Impaired renal function defined as serum-creatinine = 125 µmol/l (= 1.4 mg/dl) for males and = 110 µmol/L (= 1.3 mg/dl) for females or according to local label for metformin \\[For France: glomerular filtration rate below 60 ml/min, calculated by the Cockroft \\& Gault formula\\] at end of treatment in NN1250-3643.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)","description":"Values for change in HbA1c from baseline to 26 weeks of treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.40"},{"groupId":"OG001","value":"-0.74","spread":"0.73"},{"groupId":"OG002","value":"-0.39","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG)","description":"Values for change in FPG in mmol/L from baseline to week 26 of randomised period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"2.03"},{"groupId":"OG001","value":"-0.14","spread":"2.52"},{"groupId":"OG002","value":"-0.04","spread":"2.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"Corresponds to the values of change in body weight in kilograms from baseline to week 26.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.7"},{"groupId":"OG001","value":"-1.0","spread":"1.3"},{"groupId":"OG002","value":"0.3","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes","description":"Corresponds to number of treatment emergent hypoglycaemic events from onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product. Confirmed hypoglycaemia was defined as the pool of severe hypoglycaemic episodes and minor episodes with a plasma glucose (PG) value \\< 3.1 mmol/L (56 mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"313","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"330","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":236},"commonTop":["Nasopharyngitis","Nausea","Upper respiratory tract infection","Diarrhoea","Bronchitis"]}}}